Alimera Sciences Inc  

(Public, NASDAQ:ALIM)   Watch this stock  
Find more results for ALIM
1.36
0.00 (0.37%)
Real-time:   3:18PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.35 - 1.38
52 week 1.01 - 2.40
Open 1.35
Vol / Avg. 164,096.00/312,057.00
Mkt cap 88.27M
P/E     -
Div/yield     -
EPS -0.51
Shares 64.90M
Beta 2.17
Inst. own 76%
Aug 1, 2017
Q2 2017 Alimera Sciences Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jun 23, 2017
Alimera Sciences Inc Annual Shareholders Meeting (Estimated) - 9:30AM EDT - Add to calendar
Jun 22, 2017
Alimera Sciences Inc Annual Shareholders Meeting
May 9, 2017
Q1 2017 Alimera Sciences Inc Earnings Call - Webcast
May 8, 2017
Q1 2017 Alimera Sciences Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '17) 2016
Net profit margin -101.77% -96.62%
Operating margin -83.27% -88.58%
EBITD margin - -73.05%
Return on average assets -40.68% -47.15%
Return on average equity - -
Employees 125 -
CDP Score - -

Address

6120 Windward Pkwy Ste 290
ALPHARETTA, GA 30005-8897
United States - Map
+1-678-9905740 (Phone)
+1-678-9905744 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Alimera Sciences, Inc. (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina. The Company's product is ILUVIEN, which is developed to treat diabetic macular edema (DME). DME is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness. In the United States, ILUVIEN is indicated for the treatment of DME in patients who have been treated with a course of corticosteroids and did not have a rise in intraocular pressure (IOP). In the European Economic Area (EEA) countries, ILUVIEN is indicated for the treatment of vision impairment associated with DME considered insufficiently responsive to available therapies.

Officers and directors

Richard S. Eiswirth Jr. President, Chief Financial Officer
Age: 47
Bio & Compensation  - Reuters
Rich Cockrell President
Bio & Compensation  - Reuters
C. Daniel Myers Chief Executive Officer
Age: 62
Bio & Compensation  - Reuters
Kenneth E. Green Ph.D. Senior Vice President, Chief Scientific Officer
Age: 57
Bio & Compensation  - Reuters
David R. Holland Senior Vice President - Sales and Marketing
Age: 52
Bio & Compensation  - Reuters
Philip Ashman Senior Vice President, European Managing Director
Age: 51
Bio & Compensation  - Reuters
Mark J. Brooks Independent Director
Age: 48
Bio & Compensation  - Reuters
Brian K. Halak Ph.D. Independent Director
Age: 44
Bio & Compensation  - Reuters
Peter J. Pizzo III Independent Director
Age: 49
Bio & Compensation  - Reuters